Pharmacy Benefit Managers rig the system. They inflate prices and take advantage of community pharmacists.
That’s why I’ve introduced legislation to crack down on their shady practices and put patients first.
Thanks @RogerMarshallMD. This legislation is a huge step in the right direction ! It covers so many of the little things that are often forgotten.
https://t.co/0on72FcISd
Transparent pharmacy benefit strategies can generate substantial savings while improving healthcare access for your employees and strengthening your community.
That's why you should join us for our upcoming webinar "Redefining the “Norm” of Employee Pharmacy Benefits – PBM Contracts & Employee Impact" on May 19th, at 2 PM ET. Where we tell the story of a Kansas School District that made the decision to use a transparent, pass through PBM and the savings that they saw as a result!
This is not a sales pitch - this is a grassroots initiative inspired by @commpharmacy (NCPA) Foundation's donor, Mark Cuban, to help move the needle on price transparency and healthcare accessibility. Learn actionable strategies to identify hidden costs, restructure contracts, and create win-win scenarios for employers, employees and local communities.
Register here: https://t.co/rjaB4cWqyp
We look forward to sharing what we know with you!
SonjaPagniano, CFRE
@daredprice
NathanReed
Today, NCPA (@Commpharmacy) is joining a class action lawsuit against GoodRx and PBMs for colluding in a price-fixing scheme that harms independent pharmacies. We’re committed to holding these entities accountable and fighting for fairness. #PharmacyJustice#IndependentPharmacy
Excited to join X as NCPA (@Commpharmacy ) President! Ready to make a difference for independent pharmacies by pushing for #PBMReform, advocating for fair practices, & ensuring better care for patients. Let’s connect, collaborate & create change together. #PharmacyLeadership
1. Today @FTC published its second interim staff report on the 3 major pharmacy benefit managers.
It finds these PBMs marked up several specialty generic drugs by thousands of percent, generating them more than $7.3 billion in extra revenue from 2017-22.
https://t.co/R2XbTaEmhQ
As if today wasn’t already turning out to be a very bad day for #PBMs…
For years, the benefit managers, or P.B.M.s, took payments from opioid manufacturers, including Purdue Pharma, in return for not restricting the flow of pills. https://t.co/txMS7zURKA
@Riley_Gaines_ Instead of gaslighting, let's think about who makes a TON of money but makes no product, spend $0 on R&D (unless it's how to not pay bills), and provides zero care…. 🤔😒